Lingfei Han

751 total citations
30 papers, 574 citations indexed

About

Lingfei Han is a scholar working on Molecular Biology, Immunology and Biomedical Engineering. According to data from OpenAlex, Lingfei Han has authored 30 papers receiving a total of 574 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 8 papers in Immunology and 8 papers in Biomedical Engineering. Recurrent topics in Lingfei Han's work include Nanoplatforms for cancer theranostics (8 papers), Immune cells in cancer (5 papers) and Cancer Research and Treatments (4 papers). Lingfei Han is often cited by papers focused on Nanoplatforms for cancer theranostics (8 papers), Immune cells in cancer (5 papers) and Cancer Research and Treatments (4 papers). Lingfei Han collaborates with scholars based in China, Canada and United States. Lingfei Han's co-authors include Wenyuan Liu, Fulei Liu, Feng Feng, Jingwei Xue, Wei Qu, Xiaoxian Huang, Xuewei Liao, Bo Yin, Fang Li and Feng Feng and has published in prestigious journals such as Advanced Materials, Biomaterials and Chemical Communications.

In The Last Decade

Lingfei Han

29 papers receiving 567 citations

Peers

Lingfei Han
Lingfei Han
Citations per year, relative to Lingfei Han Lingfei Han (= 1×) peers Shey-Cherng Tzou

Countries citing papers authored by Lingfei Han

Since Specialization
Citations

This map shows the geographic impact of Lingfei Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lingfei Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lingfei Han more than expected).

Fields of papers citing papers by Lingfei Han

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lingfei Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lingfei Han. The network helps show where Lingfei Han may publish in the future.

Co-authorship network of co-authors of Lingfei Han

This figure shows the co-authorship network connecting the top 25 collaborators of Lingfei Han. A scholar is included among the top collaborators of Lingfei Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lingfei Han. Lingfei Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wu, Xiaoqian, Yanjun He, Jiaxin Zhu, et al.. (2025). Mechanistic insights into the anti-rheumatoid arthritis effects of ursolic acid from Periploca forrestii Schltr. via network pharmacology, molecular docking, and experimental Validation. Biochemical and Biophysical Research Communications. 775. 152111–152111.
3.
Yin, Bo, Jie Liu, Haoran Hu, et al.. (2025). Exosomal CMTM4 Induces Immunosuppressive Macrophages to Promote Ovarian Cancer Progression and Attenuate Anti‐PD‐1 Immunotherapy. Advanced Science. 12(30). e04436–e04436. 10 indexed citations
4.
Yin, Bo, Chun Chen, Haoran Hu, et al.. (2025). Oncogenic CMTM6 drives M2a macrophages formation and fuels cervical cancer progression. Frontiers in Immunology. 16. 1621816–1621816. 1 indexed citations
5.
Wang, Ruyi, Zhongtao Zhang, Xiaoxian Huang, et al.. (2024). Simplified Gambogic Acid Prodrug Nanoparticles to Improve Efficiency and Reduce Toxicity for Clinical Translation Potential. Advanced Healthcare Materials. 13(31). e2401950–e2401950. 7 indexed citations
6.
Liu, Bowen, Fulei Liu, Cong Li, et al.. (2023). Enhanced Anti-Rheumatoid Arthritis Activity of Total Alkaloids from Picrasma Quassioides in Collagen-Induced Arthritis Rats by a Targeted Drug Delivery System. Journal of Pharmaceutical Sciences. 112(9). 2483–2493. 3 indexed citations
7.
Zhang, Kexin, Ruyi Wang, Zongtao Zhang, et al.. (2023). Mitochondria-anchoring self-assembled nanoparticles for multi-path energy depletion: A “nano bomb” in chemo-co-starvation therapy. International Journal of Pharmaceutics. 642. 123180–123180. 7 indexed citations
8.
Chen, Jianrong, et al.. (2022). Intranasally administered thermosensitive gel for brain-targeted delivery of rhynchophylline to treat Parkinson’s disease. Colloids and Surfaces B Biointerfaces. 222. 113065–113065. 26 indexed citations
9.
Hu, Haoran, Sufang Wu, Bo Yin, et al.. (2022). EIF4A3-regulated circ_0087429 can reverse EMT and inhibit the progression of cervical cancer via miR-5003-3p-dependent upregulation of OGN expression. Journal of Experimental & Clinical Cancer Research. 41(1). 165–165. 55 indexed citations
10.
Hu, Haoran, Wei Dong, Bo Yin, et al.. (2022). A Pyroptosis-Related Gene Panel for Predicting the Prognosis and Immune Microenvironment of Cervical Cancer. Frontiers in Oncology. 12. 873725–873725. 13 indexed citations
11.
Han, Lingfei, Xiaoxian Huang, Ruyi Wang, et al.. (2022). Programmed cyclodextrin-based core–shell nanoparticles for cooperative TGF-β blockade to reverse immunosuppression post photodynamic therapy. Chemical Engineering Journal. 455. 140830–140830. 7 indexed citations
12.
Yin, Bo, et al.. (2022). Myeloid-derived suppressor cells cross-talk with B10 cells by BAFF/BAFF-R pathway to promote immunosuppression in cervical cancer. Cancer Immunology Immunotherapy. 72(1). 73–85. 15 indexed citations
13.
Han, Lingfei, Yingming Wang, Xiaoxian Huang, et al.. (2020). Specific-oxygen-supply functionalized core-shell nanoparticles for smart mutual-promotion between photodynamic therapy and gambogic acid-induced chemotherapy. Biomaterials. 257. 120228–120228. 62 indexed citations
14.
Wang, Yingming, Lingfei Han, Fulei Liu, et al.. (2020). Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras. Colloids and Surfaces B Biointerfaces. 188. 110795–110795. 54 indexed citations
15.
Sang, Mangmang, Lingfei Han, Renjie Luo, et al.. (2019). CD44 targeted redox-triggered self-assembly with magnetic enhanced EPR effects for effective amplification of gambogic acid to treat triple-negative breast cancer. Biomaterials Science. 8(1). 212–223. 42 indexed citations
16.
Han, Lingfei, Yingming Wang, Xiaoxian Huang, et al.. (2019). A stage-specific cancer chemotherapy strategy through flexible combination of reduction-activated charge-conversional core-shell nanoparticles. Theranostics. 9(22). 6532–6549. 18 indexed citations
17.
Han, Lingfei, Fulei Liu, Xin Wang, et al.. (2018). Redox-sensitive micelles for targeted intracellular delivery and combination chemotherapy of paclitaxel and all-trans-retinoid acid. Asian Journal of Pharmaceutical Sciences. 14(5). 531–542. 37 indexed citations
18.
Liu, Fulei, Lingfei Han, Xiaoxian Huang, et al.. (2018). Reticuloendothelial System Pre-Block Strategy to Improve Tumor Targeting Efficacy for Hyaluronic Acid Related Drug Delivery System. Journal of Biomedical Nanotechnology. 14(10). 1731–1743. 11 indexed citations
19.
Han, Lingfei, Wei Wang, Jiahong Lu, et al.. (2014). AAV–sBTLA facilitates HSP70 vaccine-triggered prophylactic antitumor immunity against a murine melanoma pulmonary metastasis model in vivo. Cancer Letters. 354(2). 398–406. 21 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026